A Phase 2 interventional study of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine and Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine in Meningitis, Meningococcal Meningitis and Meningococcal Infections, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 8 sites in Finland. Open to participants aged 12 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-04.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Meningitis, Meningococcal by Sanofi — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Sanofi.
Among the 24 studies in Meningitis, Meningococcal by Sanofi, this one is the 19th largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2015, is one of 6 in phase 2, and was the 20th registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →None of the 24 studies in Meningitis, Meningococcal by Sanofi is open now. The open studies under Meningitis, Meningococcal, anywhere →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 12 Months to 23 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 13 · Phase 4 3
First in 2006; this study’s year is marked. 3 started in 2015.
This study's enrollment of 188 is below the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 907 across the 23 interventional studies, 100 across the 1 observational. Of the 24 that completed or were terminated, 22 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Meningitis, Meningococcal by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to evaluate the immunogenicity and safety profile of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid (MenACYW) Conjugate vaccine when given alone compared to that of the licensed Meningococcal groups A, C, W 135 and Y (NIMENRIX®) Conjugate vaccine.
Observational objectives:
All participants received 1 dose of MenACYW Conjugate vaccine or NIMENRIX® on Day 0 and were evaluated for immunogenicity and safety profile. The duration of each participant's participation in the trial was 30 to 44 days.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
This study's enrollment of 188 is below the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Browse Meningitis, Meningococcal studies →Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
First submitted after Sanofi Pasteur became part of Sanofi.
Compared within Meningitis, Meningococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Meningitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy, meningococcal-vaccine naive toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine.
Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Healthy, meningococcal-vaccine naive toddlers aged 12 to 23 months received a single dose of NIMENRIX® vaccine.
Biological: Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine
0.5 milliliter (mL), Intramuscular (IM)
Also known as: MenACYW Conjugate vaccine
0.5 mL, IM
Also known as: NIMENRIX®
Number of Participants Reporting Solicited Injection-Site and Systemic Reaction Following Vaccination With Either MenACYW Conjugate Vaccine or NIMENRIX®
A solicited reaction was defined as an adverse reaction (AR) observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the case report form (CRF) and considered as related to vaccination. Solicited injection site reactions: Tenderness, Erythema, and Swelling. Solicited systemic reactions: Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost, and Irritability. Grade 3 solicited injection site reactions: Tenderness: cries when injected limb was moved or the movement of the injected limb was reduced; Erythema and Swelling: greater than or equal to (≥) 50 millimeter (mm). Grade 3 solicited systemic reactions: Fever: greater than \[\>\] 39.5 degree Celsius (°C); Vomiting: ≥6 episodes per 24 hours or requiring parenteral hydration; crying abnormal: \>3 hours; Drowsiness: sleeping most of the time or difficult to wake up; Appetite lost: refuses ≥3 feeds or refuses most feeds; Irritability: inconsolable.
Time frame: Day 0 up to Day 7 post-vaccination
Study participants were enrolled from 31 March 2015 to 17 July 2015 at 8 clinic centers in Finland.
| Milestone | Group 1: MenACYW Conjugate Vaccine | Group 2: NIMENRIX® |
|---|---|---|
| Started | 94 | 94 |
| Completed | 94 | 94 |
| Not completed | 0 | 0 |
A solicited reaction was defined as an adverse reaction (AR) observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the case report form (CRF) and considered as related to vaccination. Solicited injection site reactions: Tenderness, Erythema, and Swelling. Solicited systemic reactions: Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost, and Irritability. Grade 3 solicited injection site reactions: Tenderness: cries when injected limb was moved or the movement of the injected limb was reduced; Erythema and Swelling: greater than or equal to (≥) 50 millimeter (mm). Grade 3 solicited systemic reactions: Fever: greater than \[\>\] 39.5 degree Celsius (°C); Vomiting: ≥6 episodes per 24 hours or requiring parenteral hydration; crying abnormal: \>3 hours; Drowsiness: sleeping most of the time or difficult to wake up; Appetite lost: refuses ≥3 feeds or refuses most feeds; Irritability: inconsolable.
| Participants | Group 1: MenACYW Conjugate Vaccine | Group 2: NIMENRIX® |
|---|---|---|
| Any Injection site tenderness | 28 | 31 |
| Grade 3 Injection site tenderness | 0 | 1 |
| Any Injection site erythema | 29 | 33 |
| Grade 3 Injection site erythema | 2 | 1 |
| Any Injection site swelling | 14 | 17 |
| Grade 3 Injection site swelling | 1 | 3 |
| Any Fever | 7 | 4 |
| Grade 3 Fever | 1 | 0 |
| Any Vomiting | 4 | 5 |
| Grade 3 Vomiting | 0 | 0 |
| Any Abnormal crying | 31 | 37 |
| Grade 3 Abnormal crying | 1 | 0 |
| Any Drowsiness | 32 | 26 |
| Grade 3 Drowsiness | 0 | 0 |
| Any Loss of appetite | 22 | 34 |
| Grade 3 Loss of appetite | 1 | 1 |
| Any Irritability | 49 | 53 |
| Grade 3 Irritability | 0 | 2 |
Collected over Unsolicited adverse events (AEs) data were collected from Day 0 up to Day 30 post-vaccination. The solicited reactions (SRs) were collected up to Day 7 after vaccination. Serious AEs were collected throughout the trial (up to 30 days after vaccination).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: MenACYW Conjugate Vaccine | 0/94 (0%) | 1/94 (1.1%) | 49/94 (52.1%) |
| Group 2: NIMENRIX® | 0/94 (0%) | 0/94 (0%) | 53/94 (56.4%) |
| Event | Group 1: MenACYW Conjugate Vaccine | Group 2: NIMENRIX® |
|---|---|---|
| Ligament injuryInjury, poisoning and procedural complications | 1/94 | 0/94 |
| Wrist fractureInjury, poisoning and procedural complications | 1/94 | 0/94 |
| Event | Group 1: MenACYW Conjugate Vaccine | Group 2: NIMENRIX® |
|---|---|---|
| IrritabilityPsychiatric disorders | 49/94 | 53/94 |
| Abnormal cryingPsychiatric disorders | 31/94 | 37/94 |
| Loss of appetiteMetabolism and nutrition disorders | 22/94 | 34/94 |
| Injection site ErythemaGeneral disorders | 29/94 | 33/94 |
| DrowsinessNervous system disorders | 32/94 | 26/94 |
| Injection site TendernessGeneral disorders | 28/94 | 31/94 |
| Injection site SwellingGeneral disorders | 14/94 | 17/94 |
| Upper respiratory tract infectionInfections and infestations | 8/94 | 16/94 |
| NasopharyngitisInfections and infestations | 9/94 | 5/94 |
| DiarrhoeaGastrointestinal disorders | 8/94 | 4/94 |
The analysis was performed on safety analysis set which included those participants who had received at least 1 dose of the study vaccine and had any safety data available.
| Age, Continuous(years) | Group 1: MenACYW Conjugate Vaccine | Group 2: NIMENRIX® | Total |
|---|---|---|---|
| Mean | 1.44 ± 0.302 | 1.47 ± 0.314 | 1.45 ± 0.308 |
| Sex: Female, Male(Participants) | Group 1: MenACYW Conjugate Vaccine | Group 2: NIMENRIX® | Total |
|---|---|---|---|
| Female | 37 | 53 | 90 |
| Male | 57 | 41 | 98 |
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Mar 2015 to primary completion in Aug 2015, 4 months.
Results were first posted in Jun 2020, 4 years 9 months after primary completion. A results delay was requested in Sep 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi Pasteur, a Sanofi Company →